INTRODUCTION
Polypharmacy and pill burden are common in patients with life-limiting illness such as cancer, heart failure, renal disease and dementia. 1 A key priority for healthcare professionals, when caring for these patients, is balancing chronic disease management and palliation of acute symptoms. An important element of this process is ensuring that the benefit of any prescribing decisions outweighs the potential risks. This can be particularly challenging, as many comorbidities are treated with chronic medications to maintain, or are prescribed to prevent further worsening of the disease state. Such preventative medications may not treat symptoms of the underlying disease; however, stopping preventative medications could, in theory, further worsen the comorbidity, resulting in the exacerbation of symptoms. 2 In the context of diminished life expectancy, prescribing preventative medications may be inappropriate given the time until benefit can be several years and patients are at increased risk of developing a drug-related toxicity due to their altering pharmacokinetic and pharmacodynamic profiles. 3 4 To assist healthcare professionals in making prescribing decisions for this patient population, a series of frameworks have been developed to promote rational prescribing and reduce the use of unnecessary and potentially harmful care. 5 6 However, despite these approaches, and the policy drivers advocating the use of preventative medication, 7 it is unclear to what extent preventative medications are prescribed for patients with life-limiting illness. Therefore, this study aimed to systematically review the peer-reviewed literature to examine the methods used to identify inappropriate prescribing of preventative medication in patients with life-limiting illness and to detail the nature of medications prescribed.
METHODS
The review was carried out and reported according to the Preferred Reporting in Systematic Reviews and Meta-analyses (PRISMA) guidelines; 8 the protocol was registered with PROSPERO CRD42014013733.
Data sources
The following databases were searched to identify relevant studies: MEDLINE (Ovid), EMBASE (Ovid), CINAHL and PsycINFO. All databases were searched from their respective start dates to April 2015; studies were limited to those reported in English. The search strategy was modified, when appropriate, to suit syntax requirements (see online supplementary appendix 1); search terms were focused to title and abstract. The bibliographies of all included studies were hand searched; information was also requested from key experts in the field relating to ongoings studies.
Study selection
To be included in the review, studies had to meet the following criteria:
1. Population: patients with life-limiting illness prescribed/ dispensed/using preventative medication. For the purposes of the review, life-limiting illness is defined as a malignant or non-malignant condition that would significantly reduce life expectancy including cancer, advanced dementia, advanced heart failure, end-stage chronic obstructive pulmonary disease (COPD) or advanced Parkinson's disease; preventative medication is defined as any medication used for primary, secondary or tertiary prevention to avert and avoid disease, including lipid-regulating medication, antihypertensive medication, antidiabetic medication, antiplatelet medication. 2. Study type: all types of observational studies including case series, cross-sectional and cohort studies in routine care. 3. Outcomes: assessed medication 'appropriateness'
(included specifically as a study aim or outcome measure) and whether preventative medication was discontinued in included studies.
Exclusion criteria
We excluded the following studies:
1. Those examining prescribing of preventative medication in populations without life-limiting illness (eg, elderly patients). 2. Those reporting prescribing/dispensing/medication use in patients with life-limiting illnesses, without assessing medication appropriateness. 3. Those reported as a conference abstract.
Study selection and screening
The initial screening of titles and abstracts was conducted independently by two reviewers (IA and LL), with a random 10% of the sample checked by a third reviewer (AT). Full-paper study inclusion and data extraction was conducted independently by two reviewers (IA and LL); the following data was extracted from included studies: study objectives, population, setting, life-limiting illness, methodology to assess medication appropriateness, primary outcome relating to inappropriate medication use, types of preventative medication (either class or individual medication), whether medication was discontinued as part of the study; comprehensiveness of reporting based on the STROBE checklist. 9 Any discrepancies were resolved through discussion and, if agreement was not reached, by consensus with the project lead (AT).
Data extraction quality appraisal
In the absence of a validated quality assessment tool suitable for all observational studies, including case series studies, we assessed the comprehensiveness of reporting using the STROBE checklist, based on 10 key items from the guideline (items 2, 3, 5, 6-8, 10, 14, 16, 22) . 9 This was done independently by two reviewers (IA and LL); any discrepancies were discussed and agreement was reached by consensus (AT).
Reporting
Owing to the heterogeneity of study methodology and outcomes, we could not use traditional meta-analytic approaches to combine individual study results. Instead, we described key study features using a narrative approach across the included studies.
RESULTS

Literature search
There were 20 343 hits generated from the initial literature search. After duplicates were removed, 13 472 studies were screened for eligibility, based on title and abstract; from this, 88 articles were selected for a fulltext review. After a full paper screen, 19 individual studies were included in the review; reasons for study exclusion were: not focused on preventative medications, not assessing medication appropriateness, not assessing patients with a life-limiting illness, paper was a review of the literature, opinion piece/editorial (figure 1); included studies are summarised in table 1.
Quality appraisal
All studies reported on the rationale, scientific background and settings of the work, as well as defining the sources of data. Two of the studies did not clearly state primary objectives, 10 11 while only one provided justification of the sample size used. 12 The remaining studies recruited participants over a defined time period (either retrospectively or prospectively) or used prespecified number of patients; neither approach stated a firm rationale or basis. Basic participant demographics, such as gender, age and details of lifelimiting illness, were reported in all but one of the studies. 13 Nine of the studies reported a funding source.
14-22
Participants
The total number of patients included in the studies was 10 220, ranging from 20 21 to 5405 patients. 20 The most common life-limiting illness described in the studies was cancer: nine studies examined medication use in different cancers, 10-12 16-18 23-25 while one study focused exclusively on patients with advanced lung cancer. 21 Four studies explored medication use in patients with dementia, 15 19 20 26 and two focused on patients with terminal illness in a palliative care environment; 13 22 the most common condition in these studies was cancer, although patients with advanced heart failure, end-stage COPD and Parkinson's disease were also included. One study explored how diabetes is managed in terminally ill patients; 27 the life-limiting illness of each patient was not stated, and the study focused exclusively on antidiabetic medication. The remaining studies included patients with advanced heart failure 14 and chronic kidney disease. 28 
Settings
Nine were based in hospitals, 10-12 14 21 23 26-28 three within palliative care settings, 13 16 22 three within outpatient oncology clinics, 17 24 25 one within a longterm care facility, 15 two within nursing homes, 19 20 and one study compared medication use for patients attending a hospice and hospital. 18 Criteria to assess medication appropriateness
The methodology used to assess medication appropriateness was wide ranging. Several studies used previously developed methodology to aid prescribing decisions in older people; 13 ). In contrast to these approaches, Lindsay et al, 12 using the current literature as an evidence base, developed and validated their own guideline, the Onc-Pal deprescribing guideline, to assess medication appropriateness.
Other studies utilised the opinion of the clinical experts to assess medication appropriateness: Fede et al 10 used this approach to develop a set of explicit criteria (eg, using a statin when there was a lack of any cardiovascular event in the prior 12 months was considered inappropriate) to determine if a medication was considered 'futile', while Rajimakers surveyed international experts to gather opinion on medication appropriateness and subsequently applied this to assess prescribing in a cohort of patients with cancer. 18 Riechelmann et al 11 also assessed medication futility but defined it as when there were no short-term benefit to patients with respect to survival, quality of life or symptom control. The methodologies developed by Fede and Riechelmann to assess medication futility were also deployed by Kotlinska-Lemieszek et al 16 and Lee et al, 23 who assessed prescribing in cohorts of patients with terminal cancer.
Todd et al assessed medication appropriateness by surveying the clinical team 21 or through a Delphi consensus of pharmacists and palliative care consultants; 22 both approaches used a conceptual framework to guide decision-making that considered: remaining life expectancy; time until benefit; goals of care and treatment targets. 5 Similarly, Holmes et al 15 also employed a Delphi process of 12 geriatricians to determine if the medication was: always appropriate, sometimes appropriate, rarely appropriate and never appropriate; the results from this study in terms of what constituents an inappropriate medication were applied to the work of Tjia et al 19 20 who explored medication use in nursing residents with advanced dementia. 
Types of inappropriate medication
The most common preventative class of medication assessed to be inappropriate were the lipid-lowering agents-the most common of which were the statins; this was reported in the majority of studies. 
DISCUSSION
The review identified a number of studies demonstrating that preventative medications are prescribed inappropriately to patients with various life-limiting illnesses. The class of medication most commonly identified as inappropriate or 'futile' were the lipid-lowering agents-with statins being the most frequent. This finding is supported by several cohort studies that show statins continue to be prescribed in patients with diminished life expectancy, 32 33 while it is also acknowledged that being diagnosed with a lifelimiting illness does not decrease statin use in that patient subgroup. 34 The use of statins in life-limiting illness has also been acknowledged by the Choosing Wisely initiative who recommend to avoid the routine use of lipid-lowering medications in patients with limited life expectancy. 35 Our review demonstrates that lipid-lowering medications are being prescribed to patients within this context, but it is too early to ascertain if this policy recommendation has changed prescribing behaviour in practice. This observation is also timely considering the policy shift across the world to lower the threshold criteria to initiate statin therapy, which will significantly increase the number of patients taking a statin for primary prevention. 36 37 Our review demonstrated a range of methodologies assessing medication appropriateness; several studies used expert opinion or based the decisions on the literature, while others utilised methodology originally developed to aid prescribing decisions in older people. Lipid-lowering agents were the class of preventative medications most commonly identified as inappropriate in our review yet studies that used the STOPP criteria, Beers Criteria or Unnecessary Drug Use Measure did not assess lipid-lowering medication as inappropriate, as this class of drugs are not part of these instruments. Indeed, as many of these instruments were originally designed to assess medication appropriateness in an elderly population, the utility in patients' with life-limiting illness may be inadequate and, in some cases, counter intuitive. Given this lack of standardisation, improving the prescribing in this context requires an approach that is specifically designed and validated for populations with lifelimiting illness. More support-possibly in the form of clear practical guidelines-should be made available to all healthcare professionals with responsibility for prescribing medication to patients with life-limiting illness.
In recent years, the term 'deprescribing'-a way of rationalising medication that provides a limited benefit to patients-has been introduced to the world of pharmaceutical care. A timely article by Scott et al, 38 presenting a simple five-step protocol to support deprescribing, define it as the systematic process of identifying and discontinuing drugs in instances in which existing or potential harms outweigh existing or potential benefits within the context of an individual's patient's care goals, current level of functioning, life expectancy, values and preferences. Indeed, our work in the context of life-limiting illness, supports the concept of deprescribing and demonstrates that it should be incorporated into all aspects of the prescribing process; many guidelines only state when to start a medication, but seldom explain when and how to discontinue or deprescribe a medication. From the studies identified in our review, only one, by Molist Brunet et al, 26 actively discontinued or deprescribed inappropriate preventative medication. For this study, over 60% of preventative medication was stopped due to a lack of an evidence base, with the majority of medication indicated for primary prevention. Unfortunately, this study did not ascertain how stopping preventative medication affected patients long-term.
There is a dearth of literature exploring how deprescribing preventative medication among patients with life-limiting illness affects patient outcomes. Garfinkel et al 39 has shown that stopping medication in a frail elderly population can be associated with improved quality of living and reduced mortality rates. At present, it is not clear if these benefits are directly transferable to stopping medication in patients with lifelimiting illnesses. Of note, a recent randomised trial on statin discontinuation in patients with anticipated life expectancy from 1 month to 1 year showed the rate of death was similar between the two groups, while the group that discontinued the statins had a longer median time-to-death (229 days compared with 190 days). 40 The trial also showed that the patients who discontinued the statins had a better quality of life, compared with those that continued statin therapy. This is significant progress, but given our work shows that antihypertensive and antidiabetic medications are also frequently -and perhaps inappropriately-prescribed to patients with life-limiting illness, it would be prudent to focus future trials on these medications to establish evidencebased approaches to deprescribing medication.
Another aspect of deprescribing also warranting further exploration is how patients perceive medication discontinuation when they have a life-limiting illness. This is clearly a complex area, but it is conceivable that when a patient is diagnosed with a lifelimiting illness, they may view the value and benefit of preventative medication differently, in a light of a change in life expectancy. This may also be true for healthcare professionals who are involved in the prescribing decisions of those patients. A study investigating decision-making associated with prescribing in elderly patients showed that general practitioners perceive discontinuing preventative medication as more challenging when compared with discontinuing medication indicated to treat acute conditions. 41 While Sand et al, 42 who explored medication use in a group of patients with advanced cancer, showed there was a desire to reduce the number of tablets they take, as the medication reminded them of their illness. A qualitative study building on these findings exploring preventative medication discontinuation in lifelimiting illness from the viewpoint of prescribers and patients would therefore be valuable.
There have been several reviews undertaken to identify inappropriate prescribing in patients with diminished life expectancy, although none have systematically reviewed the literature to examine the methods used to identify inappropriate prescribing of preventative medication in patients with life-limiting illness. The most recent, a review by Lindsay et al, 43 focused exclusively on patients with cancer and concluded that there is evidence that potentially inappropriate medications are commonly prescribed in patients with cancer. A recent review by Tjia et al, 44 who focused on intervention studies that reduced unnecessary medication in frail elderly patients, concluded that there was a lack of robust high-quality evidence in this area, and more work was needed to inform evidence-based approaches to deprescribing medication. Our work, which is the first to systematically review the literature in relation to inappropriate preventative medication use in lifelimiting illness, builds on these findings and shows many patients in this context-not just those with cancer, as identified by Lindsay et al-continue to take preventative medication inappropriately.
While we believe our results are robust and have important implications for prescribing preventative medication to patients with life-limiting illness, we acknowledge that our work has limitations. First, the definition we used for preventative medication is broad. It is possible that some medications we considered preventative included in the review also have an effect on the control of acute symptoms (eg, treating hyperglycaemia with an antidiabetic medication may relieve symptoms associated with fatigue as well as preventing long-term complications), which may be beneficial to the patient. Second, as with all reviews, this systematic review may be subject to publication bias: it is possible that observational studies that did not show inappropriate prescribing in patients with life-limiting illness have a lower chance of being published, meaning that we have overestimated the extent of inappropriate prescribing. We acknowledge these factors as limitations of our work; the results of this review should be interpreted with this in mind.
CONCLUSION
Patients with life-limiting illnesses are commonly prescribed preventative medications that are considered inappropriate in the context of diminished life expectancy. The way in which preventative medication appropriateness is assessed in patients with life-limiting illness varies considerably-with some methodologies utilising criteria that were previously developed for elderly populations. Given the lack of standardisation, improving the prescribing for patients with life-limiting illness requires a new approach. Consideration should therefore be given to incorporating deprescribing approaches into clear practical treatment guidelines.
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